Newron reports positive mid-stage pain data

Italy's Newron Pharmaceuticals is reporting that its pain-killer ralfinamide significantly reduced neuropathic pain in a mid-stage trial. In addition, researchers said that the drug was well tolerated with side affects that were commensurate with a placebo. Analysts dubbed the news as an encouraging sign that the therapy merited further development, sending Newron's shares up in early trading. A Phase IIb trial is scheduled to get underway later this year. Analysts are now shifting their focus to safinamide, Newron's lead candidate for Parkinson's, which is due to deliver late-stage results.

- here's the AFX report

Related Articles:
FDA OKs Newron trials. Report
Italy's Newron gains $99 million in IPO. Report
Newron launches a Phase III trial on eve of IPO. Report

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.